Nexstim’s H121 report highlights its strategic focus is firmly on exploiting the commercial potential of the SmartFocus NBT system in depression, where its unique navigation capabilities are a clear differentiator. The strengthened balance sheet removes near-term uncertainty and allows investment in generating compelling clinical data. Priorities are to maintain the growth momentum of both NBT and NBS, particularly in the key US market, and to undertake trials to position NBT as the system of choice for the emerging accelerated therapy protocols in severe depression. Reflecting the commercial and financial progress achieved in the past year, we raise our valuation to €59.1m (€8.84/share).
19 Aug 2021
Accelerated protocols could be a game changer
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Accelerated protocols could be a game changer
Nexstim PLC (0W8N:LON) | 0 0 0.0%
- Published:
19 Aug 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
25
Nexstim’s H121 report highlights its strategic focus is firmly on exploiting the commercial potential of the SmartFocus NBT system in depression, where its unique navigation capabilities are a clear differentiator. The strengthened balance sheet removes near-term uncertainty and allows investment in generating compelling clinical data. Priorities are to maintain the growth momentum of both NBT and NBS, particularly in the key US market, and to undertake trials to position NBT as the system of choice for the emerging accelerated therapy protocols in severe depression. Reflecting the commercial and financial progress achieved in the past year, we raise our valuation to €59.1m (€8.84/share).